Origin Materials, Inc. (NASDAQ:ORGN) is a technology company that focuses on creating sustainable materials. On November 14, 2024, ORGN reported its third-quarter earnings, revealing an earnings per share (EPS) of -$0.26, which was below the expected -$0.11. The company's revenue was approximately $8.2 million, missing the estimated $9.1 million.
During the Q3 2024 earnings call, key figures like Co-CEOs Rich Riley and John Bissell, and CFO Matt Plavan, discussed the company's performance. Despite the earnings miss, ORGN achieved a milestone with its CapFormer System, which showed over 98% manufacturing efficiency. This system is set to produce the first commercially viable PET caps, with commercial production expected by year-end.
The price-to-sales ratio of 4.52 suggests investors are paying $4.52 for every dollar of sales. The enterprise value to sales ratio of 3.20 provides a perspective on the company's valuation compared to its sales.
ORGN's financial health is mixed. The enterprise value to operating cash flow ratio is -1.90, indicating negative operating cash flow. However, the company maintains a low debt-to-equity ratio of 0.027, showing minimal debt compared to equity. Additionally, a strong current ratio of 16.27 suggests ORGN can easily cover its short-term liabilities with its assets.
Symbol | Price | %chg |
---|---|---|
BRPT.JK | 1655 | -0.3 |
051910.KS | 229000 | 7.64 |
051915.KS | 115700 | 7.78 |
4063.T | 4735 | -0.78 |
Origin Materials, Inc. (NASDAQ:ORGN) is a technology company that focuses on creating sustainable materials. On November 14, 2024, ORGN reported its third-quarter earnings, revealing an earnings per share (EPS) of -$0.26, which was below the expected -$0.11. The company's revenue was approximately $8.2 million, missing the estimated $9.1 million.
During the Q3 2024 earnings call, key figures like Co-CEOs Rich Riley and John Bissell, and CFO Matt Plavan, discussed the company's performance. Despite the earnings miss, ORGN achieved a milestone with its CapFormer System, which showed over 98% manufacturing efficiency. This system is set to produce the first commercially viable PET caps, with commercial production expected by year-end.
The price-to-sales ratio of 4.52 suggests investors are paying $4.52 for every dollar of sales. The enterprise value to sales ratio of 3.20 provides a perspective on the company's valuation compared to its sales.
ORGN's financial health is mixed. The enterprise value to operating cash flow ratio is -1.90, indicating negative operating cash flow. However, the company maintains a low debt-to-equity ratio of 0.027, showing minimal debt compared to equity. Additionally, a strong current ratio of 16.27 suggests ORGN can easily cover its short-term liabilities with its assets.